BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 9
• 10
• 11
• 12
• 13
• 16
• 17
• 18
• 19
• 20
• 23
• 24
• 25
• 26
• 27
• 29
• 30
• 31

• Press Releases

  Investigational Epcoritamab (DuoBody® CD3xCD20) Combination Therapy Demonstrates High Response Rates in Clinical Trial of Patients With Relapsed or Refractory (R/R) Follicular Lymphoma (FL)

  December 9, 2024

   · 

  14 min read
• Press Releases

  DARZALEX® (daratumumab) subcutaneous formulation shows 51 percent reduction in risk of progression to active multiple myeloma for patients with high-risk smouldering multiple myeloma

  December 9, 2024

   · 

  14 min read
• Press Releases

  C4 Therapeutics Presents Cemsidomide Phase 1 Data at the American Society for Hematology (ASH) Annual Meeting that Demonstrated Potential to Become Best-in-Class IKZF1/3 Degrader

  December 9, 2024

   · 

  12 min read
• Press Releases

  Longer-term data for Novartis Scemblix® reinforce superior efficacy with favorable safety and tolerability profile in adults with newly diagnosed CML

  December 9, 2024

   · 

  15 min read
• Press Releases

  AbbVie Announces Emotional Impact Report on Mental Health of Underrepresented CLL Cancer Patients

  December 9, 2024

   · 

  9 min read
• Press Releases

  Merck’s Investigational Zilovertamab Vedotin in Combination With R-CHP Demonstrates Complete Response Rate of 100% at 1.75 mg/kg Dose in Phase 2 Trial of Previously Untreated Patients With Diffuse Large B-Cell Lymphoma

  December 9, 2024

   · 

  9 min read
• Press Releases

  DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj)-based regimens demonstrate improved rates of minimal residual disease (MRD) negativity and progression-free survival in patients with newly diagnosed multiple myeloma

  December 9, 2024

   · 

  32 min read
• Press Releases

  Orca Bio Presents Three-Year Survival Data with Orca-T® in Patients with Hematological Malignancies at the 66th ASH Annual Meeting

  December 9, 2024

   · 

  6 min read
• Press Releases

  2024 ASH Oral Presentation----Abbisko presents promising preliminary phase 2 study results of pimicotinib in the treatment of Chronic Graft-versus-Host Disease (cGvHD) at the 66th ASH Annual Meeting

  December 9, 2024

   · 

  3 min read
• Press Releases

  Leukogene Therapeutics Welcomes Industry Veteran and Leader Dr. Sandeep Gupta as Its Chief Executive Officer

  December 9, 2024

   · 

  2 min read